Stroma Therapeutics is an early-stage biotechnology spinout based on the translational research from Dr Ingo Ringshausen’s laboratory within the Department of Haematology and Cambridge Stem Cell Institute.
The proposed University of Cambridge spinout aims to develop therapeutics that specifically target pathways in the tumour microenvironment which are critically relied upon by a number of cancers. By targeting conserved dependencies on the neighbouring environment, cancers are more susceptible to existing chemotherapies, with no additional side effects observed. Our mission is to treat the whole disease, not just the tumour but also its micro-environment, to enable better outcomes for many cancers with unmet medical need.